Abstract
Aim: To evaluate safety and efficacy of reconstituted atropine 0.01% eye drops for Indian children with myopic progression.
 Methods: Fifty children with progressive myopia with their spherical equivalent increasing at least 0.75 D in 6 months (0.75 to 1.50 D) were put on reconstituted atropine 0.01%. Ocular examination, including near vision, near point of accommodation (NPA), pupil size and axial length, was done. Subjective symptoms of glare and photophobia were noted. Systemic side effects were documented. Analysis was done using Microsoft Excel 2010.
 Results: The average age of patients was 9.5 years (range 5 to 14 years) and they were followed up for 1 year. Average mesopic and photopic pupil size was 5 and 4 mm, respectively. Average NPA was 9 cm. Mean increase in spherical equivalence was 0.18 D over 6 months. Average increase in axial length was 0.12 ± 0.11 mm over 6 months and 0.2 ± 0.29 mm over 1 year. Average increase in spherical equivalent over 6 months was 0.07 ± 0.19 D and over 1 year was 0.32 ± 0.29 D. No systemic side effects were recorded.
 Conclusion: Reconstituted atropine 0.01% eye drops is safe and efficacious in slowingthe progression of myopia in Indian children.
Highlights
Myopia is one of the most common ocular disorders in the world and considered to be the leading cause of visual impairment.[1]
Various surveys in India have found myopia prevalence ranging from 6.9% to 19.7%
The mechanisms involved in the aetiology of myopia are unclear and both environmental and genetic factors have been associated with the onset and progression of myopia.[1,5,6]
Summary
Myopia is one of the most common ocular disorders in the world and considered to be the leading cause of visual impairment.[1] Various prevalence studies have shown a substantial increase in myopia among adolescents and it is thought to be approaching 10% to 25% in the West and 60% to 80% in the East.[2] Various surveys in India have found myopia prevalence ranging from 6.9% to 19.7%.3,4. There have been numerous studies on this subject. Evidence from randomized controlled trials has become available only over the last two decades These trials confirm that atropine eye drops are effective in the control of myopia in a dose-dependent manner.[7,8,9,10]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
